Beam Therapeutics Inc Share Price Today: Live Updates & Key Insights

Beam Therapeutics Inc share price today is $25.6589, up -2.15%. The stock opened at $25.02 against the previous close of $25.17, with an intraday high of $25.8 and low of $24.6.

Beam Therapeutics Inc Share Price Chart

Beam Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Beam Therapeutics Inc Share Price Performance

$25.6589 -0.0215(-2.15%) BEAM at 23 Mar 2026 12:11 PM Biotechnology
Lowest Today 24.6
Highest Today 25.8
Today’s Open 25.02
Prev. Close 25.17
52 Week High 36.44
52 Week Low 13.53
Day’s Range: Low 24.6 High 25.8
52-Week Range: Low 13.53 High 36.44
1 day return -
1 Week return -3.25
1 month return -12.98
3 month return -11.64
6 month return +0.9
1 year return +2.62
3 year return -19.6
5 year return -74.0
10 year return -

Beam Therapeutics Inc Institutional Holdings

ARK Investment Management LLC 12.24

FMR Inc 11.69

Farallon Capital Management, L.L.C. 9.88

Vanguard Group Inc 9.03

ARK Disruptive Innovation Full Composite 8.57

ARK Innovation ETF 8.54

BlackRock Inc 8.00

Sumitomo Mitsui Trust Group Inc 4.74

ARCH VENTURE CORP 4.46

Amova Asset Management Americas, Inc 4.33

Fidelity Growth Compy Commingled Pl S 4.28

State Street Corp 3.94

Fidelity Growth Company Fund 3.16

State Street® SPDR® S&P® Biotech ETF 2.91

BB Biotech AG Ord 2.84

Vanguard Total Stock Mkt Idx Inv 2.83

Amova ARK Disruptive Innovation A USD 2.69

Kynam Capital Management, LP 2.40

Geode Capital Management, LLC 2.31

iShares Russell 2000 ETF 2.28

MWG Management Ltd. 2.23

T. Rowe Price Associates, Inc. 2.22

ARK Genomic Revolution ETF 2.18

ARK Genomic Revolution 2.13

Vanguard Small Cap Index 2.03

Dimensional Fund Advisors, Inc. 1.91

UBS Asset Mgmt Americas Inc 1.64

Casdin Capital, LLC 1.57

Contrarius Global Equity Institutional 1.40

Redmile Group, LLC 1.36

The Goldman Sachs Group Inc 1.29

MWG Caph Ltd 1.24

T. Rowe Price Health Sciences 1.14

Vanguard Small Cap Growth Index Inv 1.13

Amova ARK Pstv Chg Innovt P JPY Acc 1.13

UBS Group AG 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.05

Fidelity Small Cap Index 0.92

Fidelity Growth Company K6 0.91

Fidelity Series Growth Company 0.87

Beam Therapeutics Inc Market Status

Strong Buy: 10

Buy: 4

Hold: 3

Sell: 0

Strong Sell: 0

Beam Therapeutics Inc Fundamentals

Market Cap 2508.72 M

PB Ratio 2.0707

PE Ratio 0.0

Enterprise Value 1472.63 M

Total Assets 1481.18 M

Volume 3102434

Beam Therapeutics Inc Company Financials

Annual Revenue FY25:139743000 139.7M, FY24:63518000 63.5M, FY23:81554000 81.6M, FY22:60920000 60.9M, FY21:51844000 51.8M

Annual Profit FY25:117449000 117.4M, FY24:63518000 63.5M, FY23:null 0.0M, FY22:60920000 60.9M, FY21:51844000 51.8M

Annual Net worth FY25:-79992000 -80.0M, FY24:-376742000 -376.7M, FY23:-313673000 -313.7M, FY22:-263588000 -263.6M, FY21:-341360000 -341.4M

Quarterly Revenue Q4/2025:114109000 114.1M, Q3/2025:9698000 9.7M, Q2/2025:8466000 8.5M, Q1/2025:7470000 7.5M, Q3/2024:14269000 14.3M

Quarterly Profit Q4/2025:402158000 402.2M, Q3/2025:-100071000 -100.1M, Q2/2025:-93292000 -93.3M, Q1/2025:-91346000 -91.3M, Q3/2024:8794000 8.8M

Quarterly Net worth Q4/2025:244297000 244.3M, Q3/2025:-112728000 -112.7M, Q2/2025:-102291000 -102.3M, Q1/2025:-109270000 -109.3M, Q3/2024:-96668000 -96.7M

About Beam Therapeutics Inc & investment objective

Company Information Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 511

Industry Biotechnology

CEO Mr. John M. Evans M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Beam Therapeutics Inc FAQs

What is the share price of Beam Therapeutics Inc today?

The current share price of Beam Therapeutics Inc is $25.6589.

Can I buy Beam Therapeutics Inc shares in India?

Yes, Indian investors can buy Beam Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Beam Therapeutics Inc shares in India?

You can easily invest in Beam Therapeutics Inc shares from India by:

Can I buy fractional shares of Beam Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Beam Therapeutics Inc?

Beam Therapeutics Inc has a market cap of $2508.72 M.

In which sector does Beam Therapeutics Inc belong?

Beam Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Beam Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Beam Therapeutics Inc?

The PE ratio of Beam Therapeutics Inc is N/A and the PB ratio is 2.07.